Sinopharm Chuankang Pharmaceutical Co. Ltd.

Primary Objective: To evaluate the pharmacokinetic parameters of tacrolimus extended-release capsules (1 mg) manufactured by Sinopharm Sichuan Kang Pharmaceutical Co., Ltd. and tacrolimus extended-release capsules (trade name: Xinpulekefu®, 1 mg) certified by Astellas Pharma Europe B.V., using a single-center, randomized, open-label, single-dose, two-formulation, two-sequence, four-period, fully replicated crossover trial design, and to assess the bioequivalence of the reference formulation and the test formulation in humans under fasting and postprandial conditions. Secondary Objective: To observe the safety of the test and reference formulations in healthy participants.

Primary objective: To evaluate the pharmacokinetic parameters of Ailamod tablets (25mg) manufactured by Sinopharm Sichuan Kang Pharmaceutical Co., Ltd. and Ailamod tablets (trade name: Aidexin®, 25mg) certified by Hainan Xiansheng Pharmaceutical Co., Ltd., using a single-center, randomized, open-label, single-dose, two-formulation, two-period, self-crossover design, and to evaluate the bioequivalence of the reference and test formulations in humans under fasting and postprandial conditions. Secondary objective: To observe the safety of the test and reference formulations in healthy participants.

Primary Objective: To evaluate the pharmacokinetic parameters of iguratimod tablets (25 mg) produced by Sinopharm Sichuan Kang Pharmaceutical Co., Ltd. and iguratimod tablets (25 mg, trade name: Edixin®) produced by Hainan Xiansheng Pharmaceutical Co., Ltd. using a single-center, randomized, open-label, single-dose, two-formulation, two-period, self-crossover design. The aim was to assess the bioequivalence of the reference formulation and the test formulation under fasting and fed conditions. Secondary Objective: To observe the safety of the test and reference formulations in healthy volunteers.